Embrex Names David Kelly Senior Director Product Management for Inovocox(TM) Coccidiosis Vaccine

Embrex Names David Kelly Senior Director Product Management for
Inovocox(TM) Coccidiosis Vaccine 


RESEARCH TRIANGLE PARK, N.C., Sept. 1  /PRNewswire-FirstCall/ -- David Kelly
recently joined Embrex, Inc., (NASDAQ:EMBX), The In Ovo Company(R), as Senior
Director Product Management, Inovocox(TM). Mr. Kelly is responsible for
management of and planning for the introduction of the Inovocox(TM) in ovo (in
the egg) coccidiosis vaccine upon approval from the U.S. Department of
Agriculture. He reports to Brian Hrudka, Vice President of Global Marketing and
Vice President of Latin America.

Prior to joining Embrex, Mr. Kelly held the positions of Director of Poultry
Marketing for the Americas and Worldwide, and Director of U.S. Poultry Sales
for Schering Plough. In these positions he managed coccidiosis control products
including vaccines based on traditional technology.

"Embrex's innovative approach to treating coccidiosis intrigues me because of
its ease of delivery and because it provides a new option to producers who may
want to reduce their reliance on chemical compounds currently used to treat
this harmful parasite," said Mr. Kelly.  "My work will include further analysis
of the global coccidiosis market with an initial focus on the United States,
evaluation of the product's benefits to producers, and how to commercialize it
upon approval from the USDA.  I believe this product has a great deal of
potential to benefit to the poultry industry."

Added Mr. Hrudka: "David's knowledge of the coccidiosis market is second to
none and his decision to join the Embrex team signals to all that Embrex has a
product to watch in the coccidiosis arena.  In his previous marketing and sales
roles he became familiar with the needs of poultry producers in the United
States and globally and he took the steps necessary to address those needs. He
will apply these experiences and the knowledge gained towards an Inovocox(TM)
product introduction in the United States, followed by launches in other
countries around the world."

Mr. Kelly holds a bachelor of science degree in Agricultural Resource
Management from Arizona State University and a master's in international
business administration from The American Graduate School of International
Management (Thunderbird). He has extensive international poultry experience,
having worked for leading companies such as Con Agra, Merial Select and
Schering Plough in the United States and Latin America.

Coccidiosis

Coccidiosis is a parasitic disease of a bird's digestive system which
interferes with the growth and nutritional uptake of a bird.  Symptoms often
include weight depression, intestinal lesions, diarrhea and occasional bloody
feces.  Most producers around the world currently control this disease by
delivering prophylactic amounts of coccidiostats in the feed and water or by
administering vaccines post-hatch.  Embrex's Inovocox(TM) in ovo vaccine will
be delivered to the chick embryo automatically through the company's
Inovoject(R) automated egg injection system. It is made up of live Eimeria
oocysts of four different strains that will be delivered via a single dose
injection before hatch.  Embrex estimates that approximately $350 million each
year is spent on coccidiosis treatments worldwide.

About Embrex

Embrex, Inc., The In Ovo Company(R), headquartered in Research Triangle Park,
NC, is an international agricultural biotechnology company engaged in the
development of innovative in ovo (in the egg) solutions that meet the needs of
today's global poultry industry. The company's unique integration of several
scientific and engineering disciplines enables it to be the leading provider of
in ovo, value-added solutions with its automated injection and detection
devices as well as its select vaccines.  For additional information, visit the
company web site at http://www.embrex.com/ .

These statements involve risks and uncertainties that could cause actual
results to differ materially. Risks include without limitation the degree of
growth in the poultry industry in the U.S. and globally, competition arising in
the United States, possible decreases in production by our customers, avian
disease outbreaks in Embrex's markets, market acceptance and cost of expansion
in new geographic markets and with new products, including the Company's
ability to penetrate new markets and the degree of market acceptance of new
products, the complete commercial development of potential future products on a
cost effective basis, including Gender Sort and Inovocox(TM), and the ability
to obtain regulatory approval of products. Such approval is dependent upon a
number of factors, such as results of trials, the discretion of regulatory
officials, and potential changes in regulations. Additional information on
these risks and other factors, which could affect the Company's financial
results, is included in the Company's Forms 10-K, 10-Q and other filings with
the Securities and Exchange Commission.

Embrex(R), Bursaplex(R), Newplex(TM), Inovoject(R), Inovocox(TM), Egg
Remover(R), Vaccine Saver(R), and The In Ovo Company(R) are trademarks of
Embrex, Inc.

   CONTACT: Ellen T. Moore
            Vice President, Investor Relations
            & Corporate Communications
            [phone]


DATASOURCE: Embrex, Inc.



CONTACT: Ellen T. Moore, Vice President, Investor Relations & Corporate

Communications of Embrex, Inc., [phone] 



Web site:  http://www.embrex.com/

Copyright